KIR3DL2 is a novel target for antibody-therapy of T cell lymphomas Chester, C., Lim, S., Marie-Cardine, A., Rajasekaran, N., Sicard, H., Kim, Y., Kohrt, H. AMER ASSOC CANCER RESEARCH. 2015

View details for DOI 10.1158/1538-7445.AM2015-2473

View details for Web of Science ID 000371578505073